Clinical Trial Update: EAP of CPX-351 (VYXEOS) for Patients 60-75 Years of Age With Secondary AML

View source ↗

Summary

CPX-351 (Vyxeos) has received marketing approval for adults aged 60-75 with secondary acute myeloid leukemia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• CPX-351 (Vyxeos) (CPX-351)

Snippet

Sponsor: Jazz Pharmaceuticals | Conditions: Secondary AML | Status: APPROVED_FOR_MARKETING